---
Investor Relations
About Awakn
Awakn is a Clinical Stage Biotechnology Company Developing Therapeutics for Substance Use and Mental Health Disorders.
Awakn has a near-term focus on Alcohol Use Disorder (AUD), a condition affecting approximately 29[¹] million adults in the US and approximately 40 million [²,³,⁴,⁵,⁶] in the US and key European for which the current standard of care is inadequate.
Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need and our strategy is focused on commercialising our R&D pipeline across multiple channels.
Awakn Life Sciences Corp. Stock Price (NEO) Information provided by Stockdio.
Awakn Life Sciences Corp. (AWKN.NE)
Awakn corporate information
Download latest Awakn Corporate Presentation and visit Awakn Financials Info on Sedar.
Awakn Corporate Governance
Download latest Awakn Corporate Governance documents.
Analyst Coverage
FIRM
Stifel
Maxim Group LLC
ANALYST
Andrew Partheniou
Jason McCarthy
News
Toronto, Canada – October, 04, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics for…
TORONTO, CANADA, September 18, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing therapeutics for substance use and mental…
Toronto, Canada, August 28, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to…
Toronto, Canada, August 9, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use and…
TORONTO, CANADA, July 31, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing therapeutics for substance use and mental…
Toronto, Ontario- (July 22, 2024) – Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use and…
TORONTO, CANADA, July 18, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use and…
Enquiries
Investor relations:
Anthony Tennyson
CEO, Awakn Life Sciences
anthony.tennyson@awaknlifesciences.com
Media enquiries:
Gordo Whittaker,
CMO, Awakn Life Sciences
gordo@awaknlifesciences.com
References:
1. US Substance Abuse and Mental Health Services (SAMHSA), 2022 National Survey on Drug Use and Health
2. UK The National Institute for Health and Care Excellence (NICE) - Alcohol-use disorders diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence
3. Jahrbuch Sucht 2020 der Deutschen Hauptstelle für Suchtfragen
4. Inserm. Reducing the harm associated with alcohol consumption. Summary and recommendations. Collection Expertise collective. Montrouge: EDP Sciences, 2022.
5. Istituto Superiore di Sanità EpiCentro
6. Monografía. Alcohol 2021: Consumo y Consecuencias
Sign Up for Newsletter
MAIN OFFICE
Awakn Life Sciences Corp
301-217 Queen St. W
Toronto, Ontario M5V 0R2
Canada
© 2023 Awakn Life Sciences Corp | Privacy Policy | Disclaimer
